The BEAM Alliance urges European and national public authorities to take three key short term actions with immediate effect: (1) create a specific fund dedicated to small and medium biopharmas developing innovative antibacterial products, (2) enhance market incentives to increase the Return on Investment for products tackling antimicrobial resistance through the creation of a special status, (3) simplify regulatory pathways for products tackling antimicrobial resistance.
Download the BEAM Position Paper and the English Press Release